Co-Authors
This is a "connection" page, showing publications co-authored by JIUN-KAE JACK LEE and WILLIAM NASSIB WILLIAM JR.
Connection Strength
0.909
-
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.
Score: 0.109
-
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85.
Score: 0.096
-
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8.
Score: 0.091
-
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52.
Score: 0.090
-
Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009 Sep; 136(3):701-709.
Score: 0.084
-
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol. 2009 Feb; 32(1):15-9.
Score: 0.083
-
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.
Score: 0.082
-
Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015 Apr; 10(4):682-90.
Score: 0.032
-
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9.
Score: 0.031
-
Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10.
Score: 0.030
-
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 2013 Jun; 12(6):1112-21.
Score: 0.028
-
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6):744-51.
Score: 0.027
-
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
Score: 0.023
-
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
Score: 0.022
-
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009 Apr 15; 115(8):1713-22.
Score: 0.021
-
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
Score: 0.021
-
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604.
Score: 0.021
-
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101.
Score: 0.020